Clinical Research Abstracts of the British Equine Veterinary Association Congress 2015.
Authors: Klier J, Geis S, Steuer J, Reese S, Fuchs S, Mueller R S, Winter G, Gehlen H
Journal: Equine veterinary journal
Summary
# Editorial Summary: Nanoparticulate CpG Immunotherapy for Equine Allergic Airway Disease Recurrent airway obstruction (RAO) in horses remains a significant clinical challenge, and conventional treatments often provide incomplete resolution of respiratory compromise. Researchers in this field study investigated whether nebulised nanoparticulate CpG immunotherapy (CpG-GNP)—which works by stimulating regulatory T cells—could improve clinical outcomes either as a standalone therapy or when combined with horse-specific allergens identified through functional in vitro testing. Over a seven-week period, twenty RAO-affected horses received either CpG-GNP alone or CpG-GNP with personalised allergens via nebulisation, with clinical assessment, tracheal mucus quantification, and airway neutrophil analysis performed at baseline, post-treatment, and six weeks later. CpG-GNP monotherapy produced significant improvements in clinical parameters and notably reduced tracheal mucus production at both timepoints, whilst the allergen-enhanced protocol improved 70% of measured parameters—yet neither approach demonstrated superiority over the other. The findings suggest that CpG-GNP nebulisation may offer practitioners a novel immunomodulatory option with sustained clinical benefit for allergic airway disease, though determining optimal patient selection and integrating this approach alongside conventional management strategies will require further investigation in clinical practice.
Read the full abstract on PubMed
Practical Takeaways
- •Nebulised CpG immunotherapy may offer a novel treatment option for horses with RAO/allergic airway disease with effects persisting 6 weeks post-treatment
- •Adding horse-specific allergens to CpG therapy did not improve outcomes over CpG monotherapy, suggesting monotherapy may be sufficient and more practical
- •This immune-modulating approach targeting Treg cell stimulation represents a different therapeutic strategy from conventional RAO management
Key Findings
- •CpG-GNP nanoparticulate immunotherapy alone produced significant improvement in clinical parameters and reduction of tracheal mucus both after treatment and at 6 weeks post-treatment
- •CpG plus specific allergens improved 70% of examined parameters but showed no significant differences compared to CpG-GNP alone
- •CpG-GNP immunotherapy demonstrated potent and persistent effects on allergic and inflammatory parameters in RAO-affected horses